Claims

1. A method for treating neurotrauma, said method comprising administering to a subject having neurotrauma a therapeutically effective amount of a non-steroidal, anti-inflammatory drug (NSAID), analog, substituted form, derivative, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

2. A method according to claim 1, wherein the NSAID is intrathecally delivered.

3. A method according to claim 1, wherein the NSAID is intraventricularly delivered.

4. A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate. 2189 514/164

5. A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate. 8515 514/159 Aspirin 165

6. A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises salicylamide. 8187 514/166 863 514/165 Aspirin salicylic acid 8190

7. A method according to claim 1, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

8. A method of treating diffuse axonal injury, said method comprising administering to a subject having diffuse axonal injury a therapeutically effective amount of a naturally occurring omega conotoxin, a functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof.

9. A method according to claim 8, wherein the naturally occurring omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof is an N-type calcium channel blocker.

10. A method according to claim 8, wherein the naturally occurring omega conotoxin is selected from the group consisting essentially of GVIA and MVII.

11. A method according to claim 8, wherein said administering step further comprises intrathecally delivering the omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof.

12. A method according to claim 8, wherein said administering step further comprises intraventricularly delivering the omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof.

13. A method according to claim 8, wherein said administering step further comprises delivering the omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof to the subject through an implantable pump.

14. A method according to claim 8, wherein said administering step further comprises delivering the omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof to the subject through a spinal catheter.

15. A method according to claim 8, wherein the diffuse axonal injury is a spastic disorder.

16. A method according to claim 15, wherein the spastic disorder is caused by traumatic brain injury.

17. A method according to claim 8 further including the step of administering a non-steroidal anti-inflammatory drug to the subject.

18. A method according to claim 17, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

19. A method according to claim 17, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

20. A method according to claim 17, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

21. A method according to claim 17, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

22. A method for treating pain, said method comprising administering to a subject having pain a therapeutically effective amount of a non-steroidal, anti-inflammatory drug (NSAID), analog, substituted form, derivative, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

23. A method according to claim 22, wherein the NSAID is intrathecally delivered.

24. A method according to claim 22, wherein the NSAID is intraventricularly delivered.

25. A method according to claim 22, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

26. A method according to claim 22, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

27. A method according to claim 22, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

28. A method according to claim 22, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

29. A method for treating neuronal injury said method comprising intrathecally administering to a subject having neuronal injury a therapeutically effective amount of a non-steroidal, anti-inflammatory drug (NSAID), analog, substituted form, derivative, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.

(112 ¶ 2) what is claimed?

30. A method according to claim 29, wherein the NSAID is intraventricularly delivered.

31. A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises choline magnesium trisalicylate.

32. A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises sodium salicylate.

33. A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises salicylamide.

34. A method according to claim 29, wherein the non-steroidal anti-inflammatory drug comprises a deacetylated aspirin.

35. A method according to claim 29, wherein the neuronal injury is caused by Lupus, inflammatory neuropathy, infection, acquired disorders, transverse myelitis, Parkinson's disease, CNS vasculitis, or Alzheimer's disease.

-112 ¶1+2